China v USA

China is slowly tightening its grip on one of its most valuable resources: health data. On July 3, China’s National People’s Congress of China published a draft Data Security Law, that represents a shift in the country’s data strategy. According to the National Information Center, China will pursue “asymmetric advantages in this new round of … Read more

Recent face offs at the Sino-Indian border are part of a long-term, low-grade military conflict over a border dispute. What’s different this time is India’s response. Rather than escalate militarily, the Indian government chose to express its sovereignty by banning Chinese apps from India. This is an economic response, and one remedy that is not … Read more

The U.S. government is concerned that domestic personal and health data are at risk for improper or illegal acquisition by the Chinese government and companies related to the Chinese Communist Party (CCP), according to reports by the United States-China Economic and Security Review Commission. Such risks rise to the national security level because China’s access … Read more

According to a report by the World Bank, China is well advanced in building a national innovation system (NIS) capable of supplying the innovation and technologies needed for a growing economy that is productivity-led. Currently, the country’s NIS focuses on discovering new innovations and accelerating the diffusion of technologies throughout to support a rapidly increasing … Read more

BeiGene was founded nearly ten years ago in China. Today, the company a lot more than a cute-sounding name. It is a commercial-stage, publicly-traded biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The Chinese biotech giant raised $2 billion in a registered direct offering in July. … Read more

According to Loncar Funds, biotechnology innovation matters. Whether it is a cure for hepatitis C, new advances in cancer care, or progress against rare and debilitating diseases like cystic fibrosis, patients around the world are benefiting from unprecedented innovation that the biotech industry is delivering. Loncar Funds attributes this innovation to precision medicine. As the … Read more

Two research teams recently reported results from studies involving the long-term evaluation of non-invasive DNA fragments in blood. Evaluating these DNA fragments is called liquid biopsy, and this type of biopsy could vastly improve outcomes through early detection and low false positive rates for a wide variety of cancers. One result is Chinese and the … Read more